June 27
June 28
09:00


SUN Liming,Vice President of the Institute and Director of the IP Department, Qilu Pharmaceutical
09:35


Yongshun CHENG,Director, Beijing Intellectual Property Institute
FAN Xinmeng,Deputy Director of IP Management Center, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
ZHANG Yonghua,Partner,Commerce & Finance Law Offices
10:30
Coffee Break
11:05

Richard Ruzich,Partner, Taft Stettinius & Hollister LLP
Ian Scott,Partner, Taft Stettinius & Hollister LLP
11:40


GENG Wenjun,VP, CTTQ PHARMA
12:35
Lunch
14:00


XU Feng,Chief Intellectual Property Consultant and the Assistant Vice President of China & Asia Region, AstraZeneca (provisional)
14:35


Chunhua WU,Executive Director, Head of IP, Henlius
15:10
Topic to Be Determined
15:45
Coffee Break
16:20

WU Chunhua,Executive Director, Head of IP, Henli
16:55


Tina TAI,Partner, King & Wood Mallesons
Qian MA,Director of Biological Drug IP, Jiangsu Simcere Pharmaceutical Co., Ltd.
CAO Lili,Panter, Liu, Shen & Associates
LIU Lei,Executive Director of IP Management Center, Jiangsu Nhwa Pharmaceutical Co., Ltd.
18:00
End of the First Day of the Sub-Forum A
Interpretation of New Drug Patent Term Extension Provisions under the Implementing Rules of the Patent Law
Round-Table: Prospects for the Implementation of New Drug Patent Term Extension
Frequent Patent Invalidations - How Should Original Drug Companies Respond?
Progress of the EU pharmaceutical market data protection period and market exclusivity period Jun DENG, Patent Director, Novo Nordisk
Paragraph IV of U.S. ANDA States Patent Challenge Strategy
Round-Table: Practice of Early Resolution Mechanism for Drug Patent Disputes
IP risk management issues involved in global BD cooperation
Round-Table: Analysis of Hot Patent Invalidation Cases in the Biomedical Field
09:00

CUI Jun,Former Director, Chemical Invention Examination Department, Patent Office, China National Intellectual Property Administration
09:35


LI Caihui,Head of IP, Shanghai Dream-TopBiotechCo.,Ltd
10:10

LU Yang,Partner, RUOSHAN LAW FIRM
10:45
Coffee Break
11:20

YAO Cong,Executive Director, Head of IP, Innovent Biologics, Inc.
11:55
Overseas Patent Litigation Response Strategies

Harris GAO,Partner, Sheppard Mullin (Shanghai Office)
12:30
Lunch
14:00


QIU Fuen,Legal Director, RDPAC
14:35
15:10
16:00
End of the Sub-Forum A
Evaluation of innovation level in protection topics such as drug crystals
Discussion on issues related to drug patent experimental data
Looking at the patent protection of antibodies in China and the United States from the PCSK9 epitope patent case
Patent Layout Strategy for Innovative Pharmaceutical Companies
Judicial Practice of Pharmaceutical Technology Contracts
Expectations for the implementation of drug trial data protection system
Topic to Be Determined

Infotrans' self-media focuses on the field of IP, outputs valuable articles, discusses industry hot topics, shares practical cases, and delivers industry information. At the same time, professionals in the IP field are gathered through the IP industry forum iPiF (annual conference, held once a year), training, seminars, salons, live broadcasts, etc., to create a platform for continuous communication and learning. IP link, link to IP person! Welcome to pay attention!

For cooperation and joining the group, please contact: Raven (WeChat: 18259157913)

About IP Link
Scan the QR Code to Register: